WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference. Here are the highlights:
Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in Singapore.
The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

Dr. Wenshi Wang is the Principal Investigator of the hepatitis virus research group, Xuzhou Medical University, China. He obtained his Ph.D. from Erasmus University Rotterdam, the Netherlands, and completed post-doc research training at Heidelberg University, Germany in the field of hepatitis viruses. He has contributed more than 50 peer-reviewed publications, with 20 first or corresponding authorships in peer-reviewed academic journals such as Journal of Hepatology, Gastroenterology, Hepatology, Trends in Microbiology, Science Signaling, and JHEP Reports. He received the Kiem Award from the Royal Netherlands Society for Microbiology (2017), the EASL Sheila Sherlock Fellowship (2018) from the European Association for the Study of Liver, and the 1st Prize NVGE Gastro-intestinal Research Award from the Netherlands Society of Gastroenterology (2019). Currently, his group is committed to basic and translational research on hepatitis viruses with the following research focus:(1) Understanding the molecular and cellular mechanisms that orchestrate the hepatitis virus replication cycles; (2) Studying the host-virus interaction by employing molecular and cellular biology techniques; (3) Developing antiviral candidates and understanding their mode of action; (4) Studying the host metabolic changes and the possible consequences on virus infection.
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally advanced/metastatic solid tumor patients with KRAS G12C mutation. It involves patients with an ECOG PS of 0-1, measurable disease according to RECIST v1.1 standards. The main objectives are to determine the recommended phase II dose (RP2D) of LY3537982, its safety, pharmacokinetics (PK), and antitumor activity. Patients were divided into four dosage groups: 50 mg, 100 mg, 150 mg, and 200 mg taken twice daily. Dose expansion cohorts included combination treatments of LY3537982 with pembrolizumab (for NSCLC) and cetuximab (for CRC).
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year's AACR conference, three clinical trials were reported in the lymphoma field, including anti-CD19 immunotherapy Tafasitamab, CD19/CD20 CAR naive/memory T cells, and bispecific quadrivalent antibody (innate cell engager) AFM13.